Abstract 1054P
Background
Chimeric antigen receptor (CAR) T-cell therapy holds great promise for the treatment of solid tumors; however, how to avoid or minimize the “on-target off-tumor” effect of CAR-T therapy remains a major issue, we developed a P329G (PG) modular and switchable CAR technology, in which CAR-T cells bind tumor antigens indirectly via an Fc-silent tumor-targeting human antibody(Ab) containing the PG mutation as an adapter molecule, whose activity is controllable by the PG Ab. Here, we report the first-in-human clinical results of a CLDN18.2-targeting PG CAR-T product (IBI345) for the treatment of CLDN18.2+ solid tumors.
Methods
In this phase 1a study, patients (pts) with CLDN18.2+ advanced solid tumor received an infusion of IBI345 consisting of one dose of PG CAR-T cells at escalating doses of 50, 250×106 cells plus ≥ 1 dose of CLDN18.2-targeting PG Ab at a fixed dose of 1mg/kg Q3W after lymphodepletion preconditioning. The objectives include safety and tolerability, pharmacokinetics and preliminary efficacy (per RECIST 1.1) of IBI345.
Results
As of Apr 7, 2023, 5 pts were treated with IBI345. All 5 pts experienced TRAEs, and grade ≥ 3 TRAE were neutrophil count decreased (n=2) and decreased appetite (n=1). No CRS, ICANS or treatment-related deaths occurred. For 4 efficacy-evaluable pts (Table), 1 EGJC pt achieved PR and 2 pts (1 GC, 1 PC) achieved SD. CAR-T expansion and persistence were detected in all pts, with a median peak of 1,840 copies/μg gDNA (1,500-4,020), a median time to peak of 16 days (9-20), and a median persistence of 45 days (35-127). Table: 1054P
Overview of clinical and biomarker results for each individual patient
IBI345 | Patient | CLDN 18.2 expression | Age (years) | Gender | Tumor Type | Previous lines | Best overall response |
IBI345 PG IgG 1mg/kg + PG CAR-T cells 50*10ˆ6 | PT01 | 1+, 12%; 2+,3%; 3+, 0% | 69 | Male | Esophagogastric junction cancer (EGJC) | 2 | Partial response |
IBI345 PG IgG 1mg/kg + PG CAR-T cells 250*10ˆ6 | PT02 | 1+, 1%; 2+,0%; 3+, 0% | 64 | Male | Gastric cancer (GC) | 2 | Stable disease |
PT03 | 1+, 0%; 2+, 5%; 3+, 90% | 60 | Male | Pancreatic cancer (PC) | 2 | Stable disease | |
PT04 | 1+, 0%; 2+, 0%; 3+, 100% | 68 | Female | Pancreatic cancer (PC) | 3 | Progressive disease |
Conclusions
IBI345 demonstrated a manageable safety profile and preliminary efficacy in patients with CLDN18.2+ advanced solid tumors. To realize the full potential of this modular CAR-T cell product, the dose and regimen of the P329G Ab and CAR-T cells requires further exploration.
Clinical trial identification
NCT05199519.
Editorial acknowledgement
Weichang Chen is the corresponding author.
Legal entity responsible for the study
Innovent Cells Pharmaceuticals.
Funding
Innovent Cells Pharmaceuticals.
Disclosure
M. Li: Other, Personal, Affiliate, EMPLOYMENT: Innovent Cells Pharmaceuticals. H. Wei: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. L. Sun: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. Q. Xie: Other, Personal, Other, EMPLOYMENT: Innovent Biologics, Inc.. E. Lin: Other, Personal, Other, EMPLOYMENT: Innovent Biologics, Inc.. D. Xu: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. J. Tian: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. J. Chen: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. W. Lu: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. N. Gao: Other, Personal, Other, EMPLOYMENT: Innovent Biologics, Inc.. L. Chen: Other, Personal, Other, EMPLOYMENT: Innovent Biologics, Inc.. J. Duo: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. L. Ye: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. T. Cheng: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. Y. Sui: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. C. Klein: Other, Personal, Other, EMPLOYMENT: Roche Innovation Center Zurich. All other authors have declared no conflicts of interest.
Resources from the same session
1343P - Amivantimab as a salvage strategy post TKI (osimertinib/mobocertinib) in EGFRm NSCLC
Presenter: Bilal Krayim
Session: Poster session 19
1344P - A real-world (rw) observational study of long-term survival (LTS) and treatment patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC)
Presenter: Jorge Nieva
Session: Poster session 19
1345P - Preclinical activity of ORIC-114, a highly selective, brain penetrant, irreversible kinase inhibitor, against atypical mutations in EGFR
Presenter: Melissa Junttila
Session: Poster session 19
1346P - Efficacy and safety of high dose furmonertinib combined with intrathecal injection in EGFR-mutated advanced NSCLC patients with LM progressed on osimertinib
Presenter: Xiaoyan Li
Session: Poster session 19
1348P - Management of paresthesia in patients treated with lazertinib: Integrated analysis of LASER201 and LASER301 studies
Presenter: Yun-Gyoo Lee
Session: Poster session 19
1349P - Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases
Presenter: Molly Li
Session: Poster session 19
1350P - Survival benefits of local treatment (LT) for brain metastases (BMs) in patients (pts) with EGFR-mutant non-small cell lung cancer (EGFR-mt NSCLC) treated with osimertinib
Presenter: Takehiro Tozuka
Session: Poster session 19
1351P - Efficacy of early stereotactic body radiotherapy to the primary lung lesion in patients with NSCLC harboring sensitive EGFR mutations treated with first-line EGFR-TKIs
Presenter: Dan Tao
Session: Poster session 19
1352P - Plasma metabolic signatures uncover therapeutic response and prognosis of third-generation EGFR-TKI treatment in patients with NSCLC
Presenter: Ruyun Gao
Session: Poster session 19